coteau ARQ.

PBLS

Parabilis Medicines, Inc.
$24.44
−$2.48 (9.21%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-28%-13%+3%+19%+34%Jun 10Oct 23Aug 1652w high $42.4952w low $22.66
PBLSSPY
Wall St. Highest PT $45.00 (+84.1%) Wall St. Avg PT $41.40 (+69.4%)
$23$32$42$52$62POC $30Hi $45Avg $41
Underwater Drawdown %Max DD -45.5%Current -41.4%
0.0%-45.5%
Relative Strength vs SPY-28.0% vs SPYUnderperforming
+39%0%-39%
1W
+$1.69 (7.43%)
1M
−$8.87 (26.63%)
3M
−$6.84 (21.87%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$24.44
Average target$41.40
+$16.96 (+69.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$40.00
Median$41.40
High$45.00
12-month Wall Street target range
Recent analyst rating changes · 4
Initiated
2026-10-22 · HC Wainwright & Co. started covering PBLS at Buy
Initiated
2026-07-06 · Guggenheim started covering PBLS at Buy
Initiated
2026-07-06 · Leerink Partners started covering PBLS at Outperform
Initiated
2026-07-06 · B of A Securities started covering PBLS at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$3.0B
P/E (next 12 months, estimated)-11.2
52-week range$22.66 – $42.49
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$41.40 (+69%)

What they do

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for PBLS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

PBLS earningsNext report in 18 days
Next report
Thu Nov 12, 2026Before the open
EPS consensus-$0.38 range -$0.45–-$0.25
Revenue consensus$500.0K 3 analysts
Last 1 quarters · EPS vs estimate
Aug 13, 2026-$2.12est -$0.24−772.9%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 03:11:35 ET
26-08-2.120.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$148.0K–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
Simply Wall St. · Oct 20
Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
Simply Wall St. · Oct 20
What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
Simply Wall St. · Oct 20
Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
TIKR · Oct 19
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
GlobeNewswire · Oct 19
Rating changes
Initiated
2026-10-22 · HC Wainwright & Co. started covering PBLS at Buy
Initiated
2026-07-06 · Guggenheim started covering PBLS at Buy
Initiated
2026-07-06 · Leerink Partners started covering PBLS at Outperform
Initiated
2026-07-06 · B of A Securities started covering PBLS at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 03:11:35 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026